O-1871

O-1871 is a potent cannabinoid agonist which was invented by Billy R Martin and Raj K Razdan at Organix Inc in 2002. It has a CB1 receptor affinity of 2.0nM and a CB2 receptor affinity of 0.3nM.[1] Structurally, O-1871 is a cyclohexylphenol derivative related to CP 47,497,[2] and so is illegal in some jurisdictions where CP 47,497 and its derivatives are banned. However the 3,3-dimethylcyclohexyl substituent of O-1871 can be replaced by various other groups, producing other potent compounds such as the cycloheptyl derivative O-1656 and the 2-adamantyl derivative O-1660, as well as the corresponding 3,5-dichlorophenyl derivative,[3] which are not cyclohexylphenol derivatives.

O-1656,
O-1660,
O-1871
Clinical data
ATC code
  • none
Legal status
Legal status
  • Banned as cyclohexylphenol derivative (US, UK)
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC23H38O2
Molar mass346.555 g·mol−1
3D model (JSmol)

See also

References
  1. WO application 03091189, Martin BR, Razdan RK, "Cannabinoids", published 6 November 2003, assigned to University of Virginia
  2. Debruyne D, Le Boisselier R (2015). "Emerging drugs of abuse: current perspectives on synthetic cannabinoids". Substance Abuse and Rehabilitation. 6: 113–29. doi:10.2147/SAR.S73586. PMC 4622447. PMID 26543389.
  3. US application 2004087590, Lai XZ, Lu D, Makriyannis A, "Novel biphenyl and biphenyl-like cannabinoids", published 6 May 2004, assigned to University of Connecticut
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.